Gilead Sciences (GILD) reported a 43% dip in earnings for the first quarter due to lower product sales and prescription trends. Higher competition and lower sales of certain hepatitis C products too impacted sales during the quarter. Infographics of the results. The market has huge hopes for the company as HIV drugs are becoming more crucial to Gilead’s top-line and the hepatitis C market is stabilizing. More HIV patients are using regimens that contain a drug known as tenofovir alafenamide, or TAF. But lower sales of Harvoni and Sovaldi across all major markets and lower sales of Epclusa in the US due to increased competition hurt Gilead's product sales.
Abbvie Vpak Mole here Just riding the wave folks... should have taken my advice. ABBV up 5.52 today sitting at 102.07 and rising!
